|By Marketwired .||
|March 25, 2014 03:54 AM EDT||
OKLAHOMA CITY, OK -- (Marketwired) -- 03/25/14 -- Cytovance Biologics, Inc., a leading full-service contract manufacturer ("CMO") of mammalian and microbial biologics, is extending its manufacturing agreement with Precision Biologics, Inc., a Texas-based clinical stage biopharmaceutical company.
Precision Biologics is advancing its clinical trials with its leading monoclonal antibody candidate -- referred to as Ensituximab or NEO-102 -- which is being developed as a therapeutic drug candidate for pancreatic and colorectal cancers. Precision has contracted Cytovance Biologics as its CMO to provide technology transfer and additional cGMP manufacturing services of NEO-102 in support of its ongoing Phase 2 clinical trials.
"With this agreement, Precision Biologics is strengthening its longstanding and growing relationship with the scientific professionals of Cytovance," said Dr. Albine Martin, COO of Precision Biologics, Inc. "Cytovance has been a valuable partner in helping us reach another milestone in our program directed towards the treatment of pancreatic and colorectal cancers."
"Our state-of-the-art facilities and experienced staff are prepared to continue the delivery of clinical materials for Precision Biologics," said Darren Head, President and Chief Executive Officer of Cytovance Biologics, Inc. "We are proud to be an established partner with Precision Biologics and support them in their expanded clinical trial program."
About Precision Biologics, Inc.
Founded in February 2012 and commencing business in late September 2012, Precision Biologics, Inc. is a clinical stage biotechnology corporation focused on developing therapeutic and diagnostic products for the early detection and treatment of cancer. Precision Biologics is uniquely positioned to create innovative therapeutics through the use of proprietary cancer vaccines, several of which have demonstrated success in human trials. For further information regarding Precision Biologics, Inc., visit www.precision-biologics.com/.
About Cytovance Biologics, Inc.
Cytovance Biologics is a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation. In addition to its cGMP manufacturing services, the company offers process development, cGMP cell banking and support services from its Oklahoma City state-of-the-art facilities. Learn more about Cytovance Biologics at www.cytovance.com.
Aug. 25, 2016 10:30 AM EDT Reads: 454
Aug. 25, 2016 09:15 AM EDT Reads: 568
Aug. 25, 2016 09:00 AM EDT Reads: 547
Aug. 25, 2016 09:00 AM EDT Reads: 3,862
Aug. 25, 2016 09:00 AM EDT Reads: 469
Aug. 25, 2016 08:45 AM EDT Reads: 2,106
Aug. 25, 2016 08:30 AM EDT Reads: 407
Aug. 25, 2016 08:30 AM EDT Reads: 532
Aug. 25, 2016 08:30 AM EDT Reads: 1,704
Aug. 25, 2016 08:15 AM EDT Reads: 1,487
Aug. 25, 2016 08:00 AM EDT Reads: 511
Aug. 25, 2016 07:15 AM EDT Reads: 1,883
Aug. 25, 2016 06:30 AM EDT Reads: 1,831
Akana has announced the availability of version 8 of its API Management solution. The Akana Platform provides an end-to-end API Management solution for designing, implementing, securing, managing, monitoring, and publishing APIs. It is available as a SaaS platform, on-premises, and as a hybrid deployment. Version 8 introduces a lot of new functionality, all aimed at offering customers the richest API Management capabilities in a way that is easier than ever for API and app developers to use.
Aug. 25, 2016 06:00 AM EDT Reads: 1,424
SYS-CON Events announced today that Isomorphic Software will exhibit at DevOps Summit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Isomorphic Software provides the SmartClient HTML5/AJAX platform, the most advanced technology for building rich, cutting-edge enterprise web applications for desktop and mobile. SmartClient combines the productivity and performance of traditional desktop software with the simp...
Aug. 25, 2016 03:30 AM EDT Reads: 2,134